查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2002821

非类固醇消炎剂市场：2026-2032年全球市场预测（依药物类别、剂型、给药途径、处方状态、上市方式、病患群体、适应症​​、最终用户和分销管道划分）

Non-steroidal Anti-inflammatory Drugs Market by Drug Class, Formulation, Route Of Administration, Prescription Status, Release Type, Patient Group, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，非类固醇消炎剂(NSAID) 市场价值将达到 246.2 亿美元，到 2026 年将成长至 262.2 亿美元，到 2032 年将达到 388.1 亿美元，复合年增长率为 6.71%。

主要市场统计数据
基准年 2025 246.2亿美元
预计年份：2026年 262.2亿美元
预测年份：2032年 388.1亿美元
复合年增长率 (%) 6.71%

对影响非类固醇消炎剂。

非类固醇消炎剂) 在临床实践和消费者自我护理中继续发挥核心作用，这主要归因于全球持续存在的疼痛、发炎和慢性肌肉骨骼疾病负担。本文概述了 NSAIDs 领域不断演变的现状，重点阐述了患者期望、监管审查和供应链压力如何相互交织，并重塑产品开发和分销趋势。

技术进步、不断变化的法规以及患者期望的变化，正在如何重塑非类固醇抗发炎药领域的竞争策略和产品创新？

在技​​术进步、监管政策调整和患者用药行为变化的推动下，非类固醇消炎剂）市场格局正经历着变革性的变化。新兴的数位疗法和远端医疗正在改变医疗服务的提供地点和决策流程，并为教育和製剂管理创造了新的切入点。同时，药物警戒和真实世界数据（REW）收集的进步正在加强安全性评估，并影响附加檔和製剂指南的更新。

评估美国累积关税调整对供应链采购、成本管理和商业性定位的营运和策略影响。

到2025年，美国累积关税调整已给整个医药供应链带来巨大的成本压力，影响采购决策、定价策略和业务永续营运。关税带来的成本上涨波及整个价值链，迫使製造商和经销商调整供应商结构、协商修改供应商合约并寻找替代原料，以维持利润率和供应的连续性。

以细分市场主导的洞察，将分销管道、给药途径、药物类别、剂型和最终用户趋势与策略决策点连结起来。

一套精细的市场细分框架揭示了临床偏好、分销管道经济效益和製剂选择之间的交集，突显了影响产品市场竞争力和渗透率的因素。基于分销管道，该市场研究将药物分为非处方药 (OTC) 和处方药，并着重分析了不同的需求因素：消费者对自我护理的重视程度影响非处方药的渗透率，而临床指南和报销制度则决定了处方药的使用。基于给药途径，该市场研究将药物分为口服、注射和外用製剂，并重点阐述了给药途径如何影响安全性监测、患者依从性和製剂研发重点。

区域分析解释了区域法规结构、支付方趋势和医疗保健模式如何推动世界各地不同的策略。

区域趋势持续影响非类固醇抗发炎药物的监管方式、报销管道和应用模式，因此，针对特定区域的策略对于商业性成功至关重要。在美洲，相关人员必须应对支付主导的准入控制、整合的分销网络以及消费者对非处方止痛药的高度依赖等复杂因素，这就需要建立相应的证据和价值沟通机制。在欧洲、中东和非洲，不同司法管辖区的法规结构和医疗保健融资模式存在显着差异，因此需要製定差异化的产品註册策略和针对特定区域的证据包装，以应对不同的标准和采购流程。

为了增强竞争优势，我们优先考虑以供应可靠性、产品差异化和基于证据的定位为重点的公司层级策略。

非类固醇抗发炎药（NSAIDs）领域的竞争格局依然有利于那些拥有可靠供应链、清晰的安全讯息和针对性临床差异化优势的公司。领先的製药公司正在透过拓展剂型、探索新型给药途径以及投资上市后安全性测试来优化其生命週期策略，从而增强医生和患者的信心。此外，一些公司正利用与专业生产商和合约开发组织（CDO）的合作关係，缩短高附加价值製剂的上市时间，降低资本密集度，并利用其在经皮和外用製剂平台方面的技术专长。

为产业领导者提供可操作的策略重点和营运措施，以降低风险、增强差异化并加速商业性绩效。

产业领导企业应采取果断行动，透过有针对性的投资和营运优化，将不断变化的市场趋势转化为竞争优势。优先考虑原材料和成品来源多元化，以降低关税和地缘政治风险，同时实施先进的情境规划，量化供应中断对营运的影响。加强药物安全检测和真实世界数据（REW）收集项目，以支持安全性评估，并促进与监管机构、支付方和配药医生的建设性对话。

透明且可重复的调查方法，结合关键相关人员的访谈和第二手资料的整合，提供了可靠的见解。

本分析所依据的研究结合了对不同相关人员的结构化一手访谈和严谨的二手资料研究，后者涵盖了提交给公共监管机构的文件、临床文献和行业出版物。一手访谈透过与临床医生、製剂决策者、采购经理和供应链高管的讨论，确定了影响产品采纳和采购的实际挑战和决策标准。二级资讯来源用于检验製剂行为趋势、监管动态和分销创新，并对一手访谈的见解进行三角验证。

策略结论强调了营运韧性、基于证据的差异化和通路合作对于保持竞争优势的重要性。

总之，受监管机构对安全性的重视、医疗服务模式的转变以及供应链重组的影响，非类固醇抗发炎药（NSAIDs）市场正经历渐进式的演变，而非快速的变革。製造商和销售团队必须透过严谨的产品组合管理、有针对性的製剂创新以及加强与支付方和分销合作伙伴的协作来应对这些变化。相关人员将价格敏感性纳入采购计划、投资于真实世界安全性证据并推行以患者为中心的服务模式的利益相关者，更有可能保持其市场地位并满足临床医生和消费者的需求。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章非类固醇消炎剂市场：依药物类别划分

  • 乙酸衍生物
    • 双氯芬酸钠
    • Ketorolac
  • Phenamate系列
    • 氟苯那敏酸
    • 甲芬那酸
  • Oxycam系统
    • Piroxicam
    • 替诺昔康
  • 丙酸衍生物
    • 氟比洛芬
    • Ibuprofen
    • 酮洛芬
    • 萘普生
  • 水杨酸
    • 阿斯匹灵
    • 二氟尼柳
  • 选择性COX-2抑制剂（昔布类药物）
    • 塞来昔布
    • 依曲昔布

第九章非类固醇消炎剂市场：依剂型划分

  • 胶囊
  • 乳霜/凝胶
  • 粉末
  • 药片

第十章：非类固醇消炎剂市场：依给药途径划分

  • 口服
  • 注射
  • 外用

第十一章非类固醇消炎剂市场：依处方状态划分

  • 非处方药
  • 仅限处方笺

第十二章非类固醇消炎剂市场：依上市剂型划分

  • 立即发布
  • 缓释
    • 控释
    • 延迟释放/肠溶包衣
    • 缓释

第十三章非类固醇消炎剂市场：依患者群体细分

  • 成人
  • 老年人
  • 儿童

第十四章非类固醇消炎剂市场：依适应症划分

  • 急性疼痛
    • 牙痛
    • 肌肉骨骼损伤（扭伤/肌肉拉伤）
    • 术后疼痛
  • 僵直性脊椎炎
  • 月经疼痛
  • 发烧/高烧
  • 偏头痛和头痛
  • 眼痛和炎症
  • 骨关节炎
  • 类风湿性关节炎

第十五章非类固醇消炎剂市场：依最终用户划分

  • 门诊手术中心
  • 居家医疗
  • 医院
  • 专科诊所

第十六章非类固醇消炎剂市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十七章非类固醇消炎剂市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十八章非类固醇消炎剂市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十九章非类固醇消炎剂市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第20章：美国非类固醇消炎剂市场

第21章：中国非类固醇消炎剂市场

第22章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbvie, Inc
  • Algen Healthcare Ltd.
  • Allegiant Health
  • Amgen Inc.
  • Amneal Pharmaceuticals LLC
  • Arcutis BIoTherapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • BASF SE
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Clearsynth Labs Limited
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • EMS SA
  • Genentech, Inc.（F. Hoffmann-La Roche AG）
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Pharbest Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Spectrum Chemical Mfg. Corp.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teikoku Seiyaku Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Verona Pharma plc
  • Viatris Inc.
Product Code: MRR-7C50F2739687

The Non-steroidal Anti-inflammatory Drugs Market was valued at USD 24.62 billion in 2025 and is projected to grow to USD 26.22 billion in 2026, with a CAGR of 6.71%, reaching USD 38.81 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 24.62 billion
Estimated Year [2026] USD 26.22 billion
Forecast Year [2032] USD 38.81 billion
CAGR (%) 6.71%

A clear and authoritative introduction to the current dynamics influencing clinical use, distribution, and lifecycle management of non-steroidal anti-inflammatory drugs

Non-steroidal anti-inflammatory drugs (NSAIDs) continue to occupy a central role in clinical practice and consumer self-care, driven by a persistent global burden of pain, inflammation, and chronic musculoskeletal conditions. This introduction frames the evolving context in which NSAIDs operate, highlighting how patient expectations, regulatory scrutiny, and supply chain pressures intersect to reshape product development and distribution dynamics.

Over the past several years, clinicians and patients have grown more discerning about safety profiles, long-term tolerability, and the therapeutic trade-offs between efficacy and adverse effects. Concurrently, digital health platforms and pharmacy retail innovations have broadened access pathways and altered purchasing patterns. In turn, manufacturers and healthcare providers must balance evidence-based therapeutic selection with pragmatic considerations such as formulary positioning, reimbursement trends, and real-world adherence. As a result, stakeholders across the value chain are rethinking clinical messaging, lifecycle management, and distribution strategies to meet shifting demand while maintaining compliance and quality standards.

How technological advances, regulatory evolution, and shifting patient expectations are reshaping competitive strategies and product innovation in the NSAID arena

The landscape for non-steroidal anti-inflammatory drugs is undergoing transformative shifts driven by technology, regulatory evolution, and changes in patient behavior. Emerging digital therapeutics and telemedicine have altered the points of care and decision-making, creating new touchpoints for education and prescription management. At the same time, advances in pharmacovigilance and real-world evidence collection are elevating safety assessment and informing label updates and prescribing guidelines.

Manufacturers are responding by prioritizing differentiated formulations, refining pharmacokinetic profiles, and investing in patient-centric packaging and adherence solutions. In parallel, payers and procurement organizations are demanding clearer value propositions, which increasingly emphasize total cost of care and outcomes rather than unit price alone. Moreover, supply chain diversification and onshoring initiatives are prompting strategic supplier relationships and inventory optimization. Taken together, these forces are reshaping competitive positioning and accelerating innovation across formulation, route of administration, and channel strategies.

Assessing the operational and strategic repercussions of cumulative tariff adjustments on supply chain sourcing, cost management, and commercial positioning in the US context

In 2025, cumulative tariff adjustments within the United States introduced material cost pressures across pharmaceutical supply chains, influencing sourcing decisions, pricing strategies, and operational resilience. Tariff-related cost increases can cascade through the value chain, prompting manufacturers and distributors to reassess supplier footprints, negotiate revised supplier agreements, and explore alternative raw material sources to preserve margins and supply continuity.

Consequently, organizations have pursued a mix of tactics, including consolidating suppliers with robust compliance track records, accelerating qualification of secondary suppliers, and evaluating regional manufacturing capacities to reduce exposure to cross-border duties. These adjustments have prompted magnified focus on total landed cost models and inventory planning to buffer volatility. At the same time, commercial teams have intensified dialogue with payers and major purchasers to articulate cost drivers and value differentiators that justify pricing adjustments. Looking forward, firms that integrate tariff sensitivity into strategic procurement and scenario planning will be better positioned to maintain product availability while safeguarding financial performance.

Segment-driven insights that connect distribution channel, administration route, drug class, formulation types, and end-user dynamics to strategic decision points

A nuanced segmentation framework reveals where clinical preferences, channel economics, and formulation choices intersect to influence product viability and adoption. Based on Distribution Channel, the market is studied across Over The Counter and Prescription, highlighting divergent demand drivers where consumer self-care priorities shape OTC traction while clinical guidelines and reimbursement determine prescription utilization. Based on Route Of Administration, the market is studied across Oral, Parenteral, and Topical, underscoring how administration mode influences safety monitoring, patient adherence, and formulation development priorities.

Based on Drug Class, the market is studied across COX-2 Inhibitors and Nonselective COX Inhibitors, reflecting distinct efficacy and safety trade-offs that inform therapeutic positioning and regulatory scrutiny. Based on Formulation, the market is studied across Capsules, Creams, Gels, Powders, Suspensions, Tablets, and Transdermal Patches, each of which carries unique manufacturing, stability, and patient-preference implications. Based on End User, the market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, demonstrating how procurement cycles, dispensing protocols, and patient access differ by channel. Integrating these segmentation lenses reveals clear vectors for differentiation in R&D investment, marketing focus, and supply chain design, and it clarifies the levers that drive product uptake and clinical acceptance across diverse care settings.

Regional intelligence explaining how distinct regulatory frameworks, payer dynamics, and care models drive differentiated strategies across global geographies

Regional dynamics continue to shape regulatory approaches, reimbursement pathways, and adoption patterns for non-steroidal anti-inflammatory therapies, and a regionally attuned strategy is essential for commercial success. In the Americas, stakeholders navigate a complex interplay of payer-driven access controls, consolidated distribution networks, and high rates of consumer engagement with OTC analgesics, requiring tailored evidence generation and value communication. In Europe, Middle East & Africa, regulatory frameworks and healthcare financing models vary markedly across jurisdictions, which drives differentiated product registration strategies and localized evidence packages to meet heterogeneous standards and procurement processes.

In the Asia-Pacific region, demographic shifts toward aging populations, expanding primary care infrastructure, and strong growth in e-pharmacy adoption are converging to increase demand for both prescription and OTC NSAID formulations. Across all regions, local manufacturing capabilities, regulatory timelines, and supply chain resilience inform launch sequencing and portfolio prioritization. Therefore, commercial teams must align regional market access strategies with local clinical practice patterns and distribution realities, and they must invest in regulatory intelligence and stakeholder engagement to accelerate adoption while maintaining compliance.

Company-level strategies that prioritize supply reliability, product differentiation, and evidence-driven positioning to strengthen competitive advantage

Competitive dynamics in the NSAID space continue to favor organizations that combine reliable supply chains, clear safety messaging, and targeted clinical differentiation. Leading pharmaceutical companies are refining lifecycle strategies by extending formulations, pursuing novel delivery mechanisms, and investing in post-marketing safety studies that reinforce confidence among prescribers and patients. In addition, several firms are leveraging partnerships with specialty manufacturers and contract development organizations to accelerate time-to-market for value-added formulations, reduce capital intensity, and access technical expertise in transdermal and topical platforms.

Strategic alliances between branded manufacturers and retail or online pharmacy chains are becoming more prevalent to secure shelf placement and consumer visibility. At the same time, product stewardship and pharmacovigilance investments have become non-negotiable differentiators, particularly as regulators and payers demand robust real-world evidence to support ongoing approvals and label updates. Firms that demonstrate operational excellence, transparent safety data, and coherent value narratives will maintain stronger relationships with payers, clinicians, and distribution partners, and they will be better positioned to defend and extend commercial relevance.

Actionable strategic priorities and operational levers for industry leaders to mitigate risk, strengthen differentiation, and accelerate commercial performance

Industry leaders should act decisively to translate evolving dynamics into competitive advantage through targeted investments and operational refinement. Prioritize diversification of raw material and finished-goods sourcing to mitigate tariff exposure and geopolitical risk, and concurrently implement advanced scenario planning that quantifies the operational impact of supply disruptions. Enhance pharmacovigilance and real-world evidence generation programs to support safety narratives and to facilitate constructive engagement with regulators, payers, and prescribers.

Furthermore, accelerate investments in differentiated formulations and patient-centric delivery systems that address adherence challenges and unmet needs, and align commercial messaging to emphasize total therapeutic value rather than unit price. Strengthen partnerships with distribution channels-hospital systems, retail pharmacies, and online pharmacies-to secure preferred placement and to tailor promotional tactics to channel-specific buying behavior. Finally, embed sustainability and quality assurance into supplier selection and manufacturing practices to meet rising stakeholder expectations and to reduce long-term operational risk.

A transparent and reproducible research methodology combining primary stakeholder interviews and secondary evidence synthesis to support robust insights

The research underpinning this analysis combined structured primary interviews with a cross-section of stakeholders and rigorous secondary research across public regulatory filings, clinical literature, and industry publications. Primary engagements included discussions with clinicians, formulary decision-makers, procurement leads, and supply chain executives to surface practical challenges and decision criteria that influence adoption and procurement. Secondary sources were used to validate trends in prescribing behavior, regulatory updates, and distribution innovations, and to triangulate findings from primary interviews.

Analytical approaches included thematic synthesis of qualitative inputs, scenario-based supply chain modeling to assess tariff impacts, and comparative assessment of formulation and channel dynamics. Quality assurance processes involved cross-validation of key assertions with multiple sources and iterative review by subject-matter experts. This methodology ensured that strategic conclusions reflect real-world stakeholder priorities and that recommended actions are grounded in defensible evidence and operational feasibility.

Strategic conclusion emphasizing operational resilience, evidence-based differentiation, and aligned channel engagement to sustain competitive relevance

In conclusion, the NSAID landscape is in a period of pragmatic evolution rather than radical upheaval, with incremental shifts driven by regulatory emphasis on safety, changing care delivery models, and supply chain realignment. Manufacturers and commercial teams must navigate these changes with disciplined portfolio management, targeted formulation innovation, and enhanced engagement with payers and distribution partners. Stakeholders that integrate tariff sensitivity into procurement planning, invest in real-world safety evidence, and pursue patient-centric delivery formats will be better positioned to sustain relevance and meet clinician and consumer needs.

Moving forward, organizations should maintain a dual focus on near-term operational resilience and medium-term clinical differentiation. By harmonizing supply chain decisions with evidence generation and channel strategies, firms can reduce exposure to external shocks while creating durable competitive advantages. Ultimately, the most successful players will combine operational rigor with a clear articulation of clinical and economic value to secure trust among clinicians, payers, and patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-steroidal Anti-inflammatory Drugs Market, by Drug Class

  • 8.1. Acetic Acid Derivatives
    • 8.1.1. Diclofenac
    • 8.1.2. Ketorolac
  • 8.2. Fenamates
    • 8.2.1. Flufenamic Acid
    • 8.2.2. Mefenamic Acid
  • 8.3. Oxicams
    • 8.3.1. Piroxicam
    • 8.3.2. Tenoxicam
  • 8.4. Propionic Acid Derivatives
    • 8.4.1. Flurbiprofen
    • 8.4.2. Ibuprofen
    • 8.4.3. Ketoprofen
    • 8.4.4. Naproxen
  • 8.5. Salicylates
    • 8.5.1. Aspirin
    • 8.5.2. Diflunisal
  • 8.6. Selective COX-2 Inhibitors (Coxibs)
    • 8.6.1. Celecoxib
    • 8.6.2. Etoricoxib

9. Non-steroidal Anti-inflammatory Drugs Market, by Formulation

  • 9.1. Capsules
  • 9.2. Creams/Gels
  • 9.3. Powders
  • 9.4. Tablets

10. Non-steroidal Anti-inflammatory Drugs Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Non-steroidal Anti-inflammatory Drugs Market, by Prescription Status

  • 11.1. Over-The-Counter
  • 11.2. Prescription Only

12. Non-steroidal Anti-inflammatory Drugs Market, by Release Type

  • 12.1. Immediate-Release
  • 12.2. Modified-Release
    • 12.2.1. Controlled-Release
    • 12.2.2. Delayed-Release/Enteric-Coated
    • 12.2.3. Extended-Release

13. Non-steroidal Anti-inflammatory Drugs Market, by Patient Group

  • 13.1. Adults
  • 13.2. Geriatric
  • 13.3. Pediatric

14. Non-steroidal Anti-inflammatory Drugs Market, by Indication

  • 14.1. Acute Pain
    • 14.1.1. Dental Pain
    • 14.1.2. Musculoskeletal Injury (Sprain/Strain)
    • 14.1.3. Postoperative Pain
  • 14.2. Ankylosing Spondylitis
  • 14.3. Dysmenorrhea
  • 14.4. Fever/Pyrexia
  • 14.5. Migraine & Headache
  • 14.6. Ophthalmic Pain & Inflammation
  • 14.7. Osteoarthritis
  • 14.8. Rheumatoid Arthritis

15. Non-steroidal Anti-inflammatory Drugs Market, by End User

  • 15.1. Ambulatory Surgical Centers
  • 15.2. Homecare
  • 15.3. Hospitals
  • 15.4. Specialty Clinics

16. Non-steroidal Anti-inflammatory Drugs Market, by Distribution Channel

  • 16.1. Hospital Pharmacies
  • 16.2. Online Pharmacies
  • 16.3. Retail Pharmacies

17. Non-steroidal Anti-inflammatory Drugs Market, by Region

  • 17.1. Americas
    • 17.1.1. North America
    • 17.1.2. Latin America
  • 17.2. Europe, Middle East & Africa
    • 17.2.1. Europe
    • 17.2.2. Middle East
    • 17.2.3. Africa
  • 17.3. Asia-Pacific

18. Non-steroidal Anti-inflammatory Drugs Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Non-steroidal Anti-inflammatory Drugs Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. United States Non-steroidal Anti-inflammatory Drugs Market

21. China Non-steroidal Anti-inflammatory Drugs Market

22. Competitive Landscape

  • 22.1. Market Concentration Analysis, 2025
    • 22.1.1. Concentration Ratio (CR)
    • 22.1.2. Herfindahl Hirschman Index (HHI)
  • 22.2. Recent Developments & Impact Analysis, 2025
  • 22.3. Product Portfolio Analysis, 2025
  • 22.4. Benchmarking Analysis, 2025
  • 22.5. Abbvie, Inc
  • 22.6. Algen Healthcare Ltd.
  • 22.7. Allegiant Health
  • 22.8. Amgen Inc.
  • 22.9. Amneal Pharmaceuticals LLC
  • 22.10. Arcutis Biotherapeutics, Inc.
  • 22.11. Astellas Pharma Inc.
  • 22.12. AstraZeneca PLC
  • 22.13. BASF SE
  • 22.14. Bayer AG
  • 22.15. Boehringer Ingelheim GmbH
  • 22.16. Bristol-Myers Squibb Company
  • 22.17. Clearsynth Labs Limited
  • 22.18. Daiichi Sankyo Company, Limited
  • 22.19. Dr. Reddy's Laboratories Ltd.
  • 22.20. Eisai Co., Ltd.
  • 22.21. Eli Lilly and Company
  • 22.22. EMS S.A.
  • 22.23. Genentech, Inc. by F. Hoffmann-La Roche AG
  • 22.24. Gilead Sciences, Inc.
  • 22.25. GlaxoSmithKline PLC
  • 22.26. Hikma Pharmaceuticals PLC
  • 22.27. Incyte Corporation
  • 22.28. Johnson & Johnson Services, Inc.
  • 22.29. Merck KGaA
  • 22.30. Novartis AG
  • 22.31. Pfizer Inc.
  • 22.32. Pharbest Pharmaceuticals, Inc.
  • 22.33. Sandoz International GmbH
  • 22.34. Sanofi S.A.
  • 22.35. Spectrum Chemical Mfg. Corp.
  • 22.36. Sun Pharmaceutical Industries Ltd.
  • 22.37. Takeda Pharmaceutical Co. Ltd.
  • 22.38. Teikoku Seiyaku Co., Ltd.
  • 22.39. Teva Pharmaceutical Industries Ltd.
  • 22.40. Verona Pharma plc
  • 22.41. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 17. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POSTOPERATIVE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POSTOPERATIVE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DYSMENORRHEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DYSMENORRHEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DYSMENORRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FEVER/PYREXIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FEVER/PYREXIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FEVER/PYREXIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MIGRAINE & HEADACHE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MIGRAINE & HEADACHE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MIGRAINE & HEADACHE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OPHTHALMIC PAIN & INFLAMMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OPHTHALMIC PAIN & INFLAMMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OPHTHALMIC PAIN & INFLAMMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)

T